Consideration should be given to a trial-off indicate two weekly dosing is supported when Dosing above 1 g/kg per day is contraindicated immunoglobulin (Ig) therapy once the patient eyesight is threatened. (A) for some IVIg products. has achieved stabilised disease or clinical remission. The minimal effective dose should be to the current product information sheet prescribed. for further information. The aim should be to use the lowest dose possible that achieves the appropriate clinical The aim should be to use the lowest dose outcome for each patient. possible that achieves the appropriate clinical Dosing above 1 g/kg per day is contraindicated outcome for each patient. for some IVIg products. to the current product information sheet for further information. BIBLIOGRAPHY AR & Dahl, MV, for the Consensus Development Group 2003, statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune ‘Consensus mucocutaneous blistering diseases’, Archives of Dermatology, vol. 139, pp. 1051–9. Daoud, YJ & Amin, KG 2006, of cost of immune globulin intravenous therapy to conventional immunosuppressive therapy in treating patients with autoimmune ‘Comparison mucocutaneous blistering diseases’, International Immunopharmacology, vol. 6, no. 4, pp. 600–6. Letko, E, Miserocchi, E, Daoud, YJ, et al 2004, nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) ‚A pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies’, Clinical Immunology, vol. 111, no. 3, pp. 303–10. Orange, JS, et al 2006, 'Use of intravenous immunoglobulin in human disease: A review of primary evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology’, Journal of Allergy and Clinical Immunology, vol. 117, no. 4, pp. S525–53. END OF DOCUMENT i
Dosing above 1 g/kg per day is contraindicated for some IVIg products. to the current product information sheet for further information. The aim should be to use the lowest dose possible that achieves the appropriate clinical outcome for each patient. Consideration should be given to a trial-off immunoglobulin (Ig) therapy once the patient has achieved stabilised disease or clinical remission. The minimal effective dose should be prescribed. The aim should be to use the lowest dose possible that achieves the appropriate clinical outcome for each patient. Dosing above 1 g/kg per day is contraindicated for some IVIg products. to the current product information sheet for further information. indicate two weekly dosing is supported when eyesight is threatened. (A) BIBLIOGRAPHY AR & Dahl, MV, for the Consensus Development Group 2003, ‘Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases’, Archives of Dermatology, vol. 139, pp. 1051–9. Daoud, YJ & Amin, KG 2006, ‘Comparison of cost of immune globulin intravenous therapy to conventional immunosuppressive therapy in treating patients with autoimmune mucocutaneous blistering diseases’, International Immunopharmacology, vol. 6, no. 4, pp. 600–6. Letko, E, Miserocchi, E, Daoud, YJ, et al 2004, ‚A nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies’, Clinical Immunology, vol. 111, no. 3, pp. 303–10. Orange, JS, et al 2006, 'Use of intravenous immunoglobulin in human disease: A review of primary evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology’, Journal of Allergy and Clinical Immunology, vol. 117, no. 4, pp. S525–53. END OF DOCUMENT i
cicatricial-pemphigoid-cp-or-mucous-membrane-pemphigoid-mmp.DOCX